SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

Home・Aktien・Pharma Mar SA

P
Pharma Mar SA

Open

99 5.54

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

92.15

Max

98.8

Schlüsselkennzahlen
By Trading Economics
Einkommen	-58M 1.6M
Verkäufe	-48M 43M
KGV Branchendurchschnitt	21.191 49.888
EPS	0.088
Gewinnspanne	3.725
Angestellte	505
EBITDA	-40M 2.7M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+27.25% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	29. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	40M 1.7B
Vorheriger Eröffnungskurs	93.46
Vorheriger Schlusskurs	99

Pharma Mar SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Pharma Mar SA Prognose

Kursziel

By TipRanks

27.25% Vorteil

12-Monats-Prognose

Durchschnitt 120.502 EUR 27.25%

Hoch 121 EUR

Tief 120 EUR

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pharma Mar SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pharma Mar SA – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.